Clinical Report: ECT2 as a Potential Biomarker for Liver Fibrosis in Biliary Atresia
Overview
This study identifies ECT2 as a biomarker for liver fibrosis and prognosis in biliary atresia (BA). Elevated serum ECT2 levels correlate with fibrosis severity.
Background
Biliary atresia is a critical cause of cholestatic liver disease in infants, leading to significant morbidity and mortality. Current diagnostic methods lack specific biomarkers.
Data Highlights
Parameter
AUC
BA Diagnosis
0.906
Liver Fibrosis Stratification
0.807
2-Year Postoperative Native Liver Survival
0.844
MMP7 for BA Diagnosis
0.924
MMP7 for Fibrosis Stratification
0.829
MMP7 for Autologous Liver Survival
0.767
Key Findings
ECT2 is significantly overexpressed in BA liver tissue and serum.
Serum ECT2 levels correlate positively with liver fibrosis severity.
ROC analysis indicates ECT2's strong diagnostic performance for BA.
ECT2 outperforms traditional liver function markers in predicting outcomes.
High serum ECT2 levels are associated with reduced postoperative native liver survival rates.
Clinical Implications
The identification of ECT2 as a biomarker may assist in diagnosis and prognostic evaluation in biliary atresia.
Conclusion
ECT2 shows potential as a non-invasive biomarker for evaluating liver fibrosis and prognosis in biliary atresia.
